Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15210569 | 0.96 | NPC1 (0.43) | KMT2AMEN1NPC1FYNRAB9A | |
| SCHEMBL15210386 | 0.91 | KMT2A (0.41) | KMT2AMEN1NPC1FYNPOLB | |
| SCHEMBL723595 | 0.87 | FYN (0.43) | KMT2AMEN1NPC1FYNRAB9A | |
| SCHEMBL16429205 | 0.87 | KMT2A (0.41) | KMT2AMEN1FYNPOLBMAPK1 | |
| SCHEMBL15210445 | 0.87 | FYN (0.42) | KMT2AMEN1NPC1FYNRAB9A | |
| SCHEMBL10267307 | 0.85 | CFTR (0.46) | KMT2AMEN1FYNPOLBSMN1; SMN2 | |
| SCHEMBL723183 | 0.85 | KMT2A (0.44) | KMT2AMEN1NPC1FYNRAB9A | |
| SCHEMBL723977 | 0.82 | CFTR (0.42) | KMT2AMEN1FYNPOLBHPGD | |
| SCHEMBL725156 | 0.80 | FYN (0.49) | KMT2ANPC1FYNRAB9APOLB | |
| SCHEMBL723443 | 0.80 | FYN (0.58) | KMT2AFYNPOLBBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2817313-B1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-09-07 | — | — | EP | claimed |
| US-20150038527-A1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-02-05 | — | — | US | claimed |
| EP-2817313-A1 | FUROPYRIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2014-12-31 | — | — | EP | claimed |
| WO-2013124025-A1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-29 | — | — | WO | claimed |
| EP-2817313-B1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-09-07 | — | — | EP | disclosed |
| US-20150038527-A1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-02-05 | — | — | US | disclosed |
| EP-2817313-A1 | FUROPYRIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2014-12-31 | — | — | EP | disclosed |
| WO-2013124025-A1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038527-A1 | FUROPYRIDINE DERIVATIVES | SYK, LYN, BTK | KMT2A 563/4885MEN1 1803/4885NPC1 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.